Hikal Q3 FY26: Revenue, EBITDA surge amid regulatory recovery
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The company has commissioned a new plant at Khanna (Punjab), which has begun commercial production
Anand Chemiceutics serves over 1,500 laboratories, hospitals, and government institutions
The revenues this quarter are in line with the outlook we envisaged for the year
The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology
The company’s EBITDA margin remained resilient above 20%
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments
Subscribe To Our Newsletter & Stay Updated